Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 1
2018 1
2021 5
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cai J, Jacob S, Kurupi R, Dalton KM, Coon C, Greninger P, Egan RK, Stein GT, Murchie E, McClanaghan J, Adachi Y, Hirade K, Dozmorov M, Glod J, Boikos SA, Ebi H, Hao H, Caponigro G, Benes CH, Faber AC. Cai J, et al. Among authors: kurupi r. Cell Rep. 2022 Jul 26;40(4):111095. doi: 10.1016/j.celrep.2022.111095. Cell Rep. 2022. PMID: 35905710 Free PMC article.
Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma.
Dalton KM, Lochmann TL, Floros KV, Calbert ML, Kurupi R, Stein GT, McClanaghan J, Murchie E, Egan RK, Greninger P, Dozmorov M, Ramamoorthy S, Puchalapalli M, Hu B, Shock L, Koblinski J, Glod J, Boikos SA, Benes CH, Faber AC. Dalton KM, et al. Among authors: kurupi r. Proc Natl Acad Sci U S A. 2021 Mar 30;118(13):e2009620118. doi: 10.1073/pnas.2009620118. Proc Natl Acad Sci U S A. 2021. PMID: 33762304 Free PMC article.
MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis.
Floros KV, Cai J, Jacob S, Kurupi R, Fairchild CK, Shende M, Coon CM, Powell KM, Belvin BR, Hu B, Puchalapalli M, Ramamoorthy S, Swift K, Lewis JP, Dozmorov MG, Glod J, Koblinski JE, Boikos SA, Faber AC. Floros KV, et al. Among authors: kurupi r. Cancer Res. 2021 Apr 1;81(7):1896-1908. doi: 10.1158/0008-5472.CAN-20-1641. Epub 2021 Jan 22. Cancer Res. 2021. PMID: 33483374 Free PMC article.
Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
Kurupi R, Floros KV, Jacob S, Chawla AT, Cai J, Hu B, Puchalapalli M, Coon CM, Khatri R, Crowther GS, Egan RK, Murchie E, Greninger P, Dalton KM, Ghotra MS, Boikos SA, Koblinski JE, Harada H, Sun Y, Morgan IM, Basu D, Dozmorov MG, Benes CH, Faber AC. Kurupi R, et al. Cancer Res Commun. 2022 Sep;2(9):1061-1074. doi: 10.1158/2767-9764.crc-21-0137. Epub 2022 Sep 26. Cancer Res Commun. 2022. PMID: 36506869 Free PMC article.
Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma.
Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D'Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mossé YP, Faber AC. Dalton KM, et al. Among authors: kurupi r. Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4. Mol Cancer Ther. 2021. PMID: 34088831 Free PMC article.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC. Lochmann TL, et al. Among authors: kurupi rij. Sci Transl Med. 2018 May 16;10(441):eaao4680. doi: 10.1126/scitranslmed.aao4680. Sci Transl Med. 2018. PMID: 29769286 Free PMC article.
Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
Heisey DAR, Jacob S, Lochmann TL, Kurupi R, Ghotra MS, Calbert ML, Shende M, Maves YK, Koblinski JE, Dozmorov MG, Boikos SA, Benes CH, Faber AC. Heisey DAR, et al. Among authors: kurupi r. Mol Cancer Ther. 2021 Oct;20(10):1868-1879. doi: 10.1158/1535-7163.MCT-20-0489. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315769
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Balko JM, et al. Among authors: kurupi r. Cancer Discov. 2014 Feb;4(2):232-45. doi: 10.1158/2159-8290.CD-13-0286. Epub 2013 Dec 19. Cancer Discov. 2014. PMID: 24356096 Free PMC article.
11 results